Eiropas Savienība - angļu - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Singapūra - angļu - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - clinical chemistry - lyphochek hypertension markers control levels is intended for use as an assayed quality control to monitor the precision of laboratory testing procedures for the analytes listed in the package insert.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). 

Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

spimaco, saudi arabia - bosentan - film-coated tablet - 125 mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: guar gum; titanium dioxide; purified talc; sodium calcium edetate; iron oxide red; citric acid; quinoline yellow aluminium lake; hypromellose; ethylcellulose; propylene glycol; carnauba wax; magnesium stearate; powdered cellulose; colloidal anhydrous silica; citric acid monohydrate - hypertension (mild, moderate to severe).

Izraēla - angļu - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar 50 mg is indicated for the treatment of hypertensionheart failure: ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to ocsaar 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

sanofi winthrop industrie - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. this fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. copalia is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,

Eiropas Savienība - angļu - EMA (European Medicines Agency)

novartis europharm limited - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, combinations, agents acting on the renin-angiotensin system, angiotensin ii antagonists and calcium channel blockers - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

novartis europharm limited - amlodipine, valsartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,